Olivier L. R. M. van Tongeren

Olivier L. R. M. van Tongeren

Auto-generated profile, based on publicly available information

Olivier L. R. M. van Tongeren

Department of Vascular Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
OTOlivier L.R.M. van Tongeren
Olivier L.R.M. van Tongeren
AVAlexander Vanmaele
Alexander Vanmaele
VRVinamr Rastogi
Vinamr Rastogi
SHSanne Elisabeth Hoeks
Sanne Elisabeth Hoeks
HVH.J.M. Verhagen
H.J.M. Verhagen
JBJorg L. de Bruin
Jorg L. de Bruin
Surveillance after endovascular aneurysm repair (EVAR) is suboptimal due to limited compliance and relatively large variability in measurement methods of abdominal aortic aneurysm (AAA) sac size after treatment. Measuring volume offers a more sensitive early indicator of aneurysm sac growth or regression/stability, but is more time consuming and thus less practical than measuring maximum diameter. This study evaluated the accuracy and consistency of the artificial intelligence (AI) driven software PRAEVAorta 2 and compared it with an established semi-automated segmentation method. Post-EVAR aneurysm sac volumes measured by AI were compared with a semi-automated segmentation method (3mensio software) in patients with infrarenal AAA, focusing on absolute aneurysm volume and volume evolution over time. The clinical impact of both methods was evaluated by categorising patients as showing either AAA sac regression, stabilisation, or growth comparing the 30 day and one year post-EVAR computed tomography angiography (CTA) images. Intermethod and intramethod agreement were assessed using Bland-Altman analysis, the intraclass correlation coefficient (ICC) and Cohen's κ statistic. Forty nine patients (98 CTA images) were analysed, after excluding 15 patients due to segmentation errors by AI owing to low quality CT scans. Aneurysm sac volume measurements showed excellent correlation (ICC = 0.94, 95% confidence interval [CI] 0.88 - 0.99) with good to excellent correlation for volume evolution over time (ICC = 0.85, 95% CI 0.75 - 0.91). Categorisation of AAA sac evolution showed fair correlation (Cohen's κ = 0.33), with 12 discrepancies (24%) between methods. The intramethod agreement for the AI software demonstrated perfect consistency (bias = -0.01 cc), indicating that it is more reliable compared with the semi-automated method. Despite some differences in AAA sac volume measurements, the highly consistent AI driven software accurately measured AAA sac volume evolution. AAA sac evolution classification appears to be more reliable than existing methods and may therefore improve risk stratification post-EVAR. It could facilitate AI driven personalised surveillance programmes. While high quality CTA images are crucial, considering radiation exposure is important, validating the software with non-contrast CT scans might reduce the radiation burden.

14 August 2024 in Journal of Endovascular Therapy
Verified
Journal Article
Open access
OTOlivier L. R. M. van Tongeren
Olivier L. R. M. van Tongeren
VRVinamr Rastogi
Vinamr Rastogi
DVDavid E. Vecht
David E. Vecht
KUKlaas H. J. Ultee
Klaas H. J. Ultee
SHSanne E. Hoeks
Sanne E. Hoeks
JBJorg L. de Bruin
Jorg L. de Bruin
Purpose: Metformin, widely used for the treatment of diabetes mellitus (DM), has shown potential for inhibiting abdominal aortic aneurysm (AAA) growth by reducing extracellular matrix remodeling and inflammation. However, its influence on clinical outcomes and aneurysm sac dynamics after endovascular aneurysm repair (EVAR) remains uncertain. This retrospective study aims to explore the effects of metformin on long-term outcomes following EVAR. Materials and Methods: Patients who underwent elective standard EVAR for infrarenal AAA at a single academic Dutch hospital from 2000 to 2022 were included. We collected baseline patient demographics, comorbid conditions, anatomical and operative characteristics, and 30-day postoperative events. Metformin use was defined as using it preceding EVAR. The primary outcome, the postoperative aneurysm sac volume over time, was investigated using linear mixed-effects modeling. The secondary outcomes, 8-year all-cause mortality and freedom from graft-related events, were evaluated using Kaplan-Meier methods. Results: We analyzed 685 patients, including 634 (93%) non-metformin users and 51 (7%) metformin users. The median follow-up period was similar (4.0 years [IQR=1.5, 6.5] vs 5.0 years [IQR=2.0, 8.0]; p=0.091). Patients on metformin had a preoperative aneurysm sac volume of 153 cc (IQR=114, 195) compared with 178 cc (IQR=133, 240) for non-metformin patients (p=0.054). At 30 days post-EVAR, metformin patients had a comparable mean aneurysm sac volume compared with non-metformin patients (metformin: –19.4 cc [95% confidence interval [CI]: –47.4, 8.5]; p=0.173). The effect of metformin on aneurysm growth over time was not significant (–3.9 cc/year; [95% CI: –22.7, 14.9]; p=0.685). Following risk-adjusted analysis, metformin use was associated with similar rates of all-cause mortality (metformin vs no metformin: 50% vs 44%; hazard ratio [HR]=1.11, 95% CI: 0.66, 1.88; p=0.688) and freedom from graft-related events (metformin vs no metformin: 63% vs 66%; HR=1.82, 95% CI: 0.98, 3.38; p=0.059). Conclusion: Although metformin use may reduce preoperative AAA growth, it does not seem to influence overall/long-term post-EVAR AAA sac dynamics, all-cause mortality, or freedom from graft-related events. These findings suggest that the potential protective effect of metformin on AAA may not be sustained after EVAR. Further prospective studies are needed to investigate the mechanisms underlying the potential role of metformin in AAA management following EVAR. Clinical Impact: There is currently no approved pharmacological treatment available to slow the abdominal aortic aneurysm (AAA) growth rate and reduce the related risk of rupture. In our retrospective analysis including 685 patients undergoing EVAR for infrarenal AAA, we found that metformin use was not associated with improved post-EVAR outcomes, such as a reduction of aneurysm sac volume over time, eight-year all-cause mortality, or freedom of graft-related events. These findings suggest that the potential protective effect of metformin on AAA may not be sustained after EVAR and underscore the need for ongoing research into this area.

8 April 2025 in Journal of Vascular Surgery
Verified
Journal Article
Open access
HLHeng Liu
Heng Liu
JBJorg L. de Bruin
Jorg L. de Bruin
AIArne S. Ijpma
Arne S. Ijpma
CCC.G.M. Castelijns
C.G.M. Castelijns
DHDaphne Heijsman
Daphne Heijsman
DMDanielle Majoor-Krakauer
Danielle Majoor-Krakauer
Aneurysms of the thoracic aorta (TAA) occur more frequently in abdominal aortic aneurysm (AAA) patients than in the general population. The aim of the study was to investigate which AAA patients have an increased risk of developing TAA or thoraco-abdominal aortic aneurysm (TAAA), and if sex, genetic susceptibility for aneurysms, or conventional cardiovascular risk factors affect this risk. Repeated CT scans from consecutively diagnosed abdominal aortic aneurysm patients were evaluated retrospectively to determine the prevalence, sequence and location of multiple aortic aneurysms. Effects of sex, genetic predisposition for aneurysms (familial aneurysm, the presence of (likely) pathogenic variants in known aneurysm genes) and cardiovascular risk factors (age, smoking, hypertension, diabetes mellitus and hypercholesterolemia) on risk for TAA were analyzed. Five-year survival was used to evaluate the impact of having thoracic aneurysms on survival of AAA patients. On the first CT scan 10.8% of AAA patients had a TAA. During follow-up an additional 5.1% of the AAA patients developed TAA and 2.4% developed TAAA. Female patients had a twofold increase in risk for TAA, in particular for aneurysms of the descending aorta. A twofold increase in risk for ascending TAA was observed in AAA patients reporting familial aneurysms. The 5-year survival of female TAAA patients was lower than that of AAA patients, independent of having a TAA. Female AAA patients had a two-fold increase in risk for TAA, particularly in the descending aorta. Familial AAA patients had a two-fold increase in aneurysm risk for ascending aortic aneurysms. TAAA patients had a lower survival compared to TAA or AAA patients, specifically among female TAAA patients. TAA and TAAA developed during follow-up. Therefore, follow-up imaging of both the ascending and descending aorta after diagnosis of AAA may improve early detection of multiple aneurysms.

20 August 2025 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
DVDavid E. Vecht
David E. Vecht
OTOlivier L.R.M. van Tongeren
Olivier L.R.M. van Tongeren
VRVinamr Rastogi
Vinamr Rastogi
FLFelix van Lier
Felix van Lier
KUKlaas H.J. Ultee
Klaas H.J. Ultee
JBJorg L. de Bruin
Jorg L. de Bruin
Peri-operative myocardial injury (PMI) is characterised by an acute but clinical asymptomatic increase in troponin levels. Its incidence in vascular surgery is underreported. Moreover, the impact of PMI on survival in patients undergoing endovascular aneurysm repair (EVAR), who are particularly at risk owing to their cardiovascular burden, remains unclear. This study aimed to assess the incidence of PMI following infrarenal EVAR and its association with long term mortality. Pre-operative and consecutive post-operative high sensitivity troponin T (hsTnT) levels were retrospectively analysed from patients who underwent standard infrarenal EVAR in a Dutch tertiary hospital between 2012 and 2022. PMI was defined as a difference of ≥ 14 ng/L (ΔhsTnT) between pre-operative and post-operative troponin concentrations without clinical features of myocardial ischaemia. Patients with clinically evident myocardial infarction were excluded. The primary outcomes were the incidence of PMI and long term mortality. A secondary outcome was the association between the magnitude of ΔhsTnT and long term mortality, irrespective of PMI criteria. A total of 318 patients were included, with a median follow up of 43 months. PMI occurred in 38 patients (11.9%). Six year risk of mortality was statistically significantly higher in patients with PMI (42.1% vs. 23.6%, adjusted hazard ratio [HR] 2.11, 95% confidence interval [CI] 1.13 - 3.92; p = .019). Age (adjusted HR 1.06, 95% CI 1.02 - 1.09; p ≤ .001) and American Society of Anesthesiologist score (adjusted HR 1.82, 95% CI 1.16 - 2.87; p = .009) were independent predictors of mortality. Statin therapy demonstrated protective advantages against mortality (adjusted HR 0.40, 95% CI 0.25 - 0.65; p < .001). Lastly, a significant association between the magnitude of ΔhsTnT and long term mortality was found (adjusted HR = 1.016/Δ 1 ng/L, 95% CI 1.004 - 1.029; p = .012). Asymptomatic PMI is relatively common following EVAR and is associated with impaired long term survival. HsTnT is a sensitive marker for identifying cardiac damage in patients undergoing EVAR. Prospective studies may strengthen the evidence of the potential association between PMI and post-EVAR mortality and clarify any benefit from intensified post-operative cardiac care.

5 October 2025 in Journal of Endovascular Therapy
Verified
Journal Article
Open access
OTOlivier L.R.M. van Tongeren
Olivier L.R.M. van Tongeren
ASAmber Sharman
Amber Sharman
VRVinamr Rastogi
Vinamr Rastogi
RVRens B. Varkevisser
Rens B. Varkevisser
SHSanne E. Hoeks
Sanne E. Hoeks
JBJorg L. de Bruin
Jorg L. de Bruin
Introduction: Thoracic endovascular aortic repair (TEVAR) is the predominant treatment for thoracic aortic aneurysms (TAA) due to its superior perioperative outcomes. International guidelines recommend assessing TAA characteristics via computed tomography angiography (CTA). However, the lack of a standardized measurements protocol introduces variability in preoperative planning, and imaging surveillance, and therefore hinders artificial intelligence (AI) integration for fully automated measurements. This study aims to develop and validate a standardized measurement protocol for TAA to improve consistency in measurement and enhance imaging surveillance. Methods: A retrospective cohort study was performed at a Dutch tertiary center on patients who underwent TEVAR for a descending TAA from 2010 to 2019. We included degenerative and mycotic TAAs, and exclusions were the lack of a preoperative CTA and/or incomplete postoperative imaging. A standardized measurement protocol was developed based on expert opinion and validated endovascular aortic repair (EVAR) protocols. Imaging analysis utilized dedicated 3D imaging software. The protocol included semi-automated 3D segmentation, center lumen line (CLL) reconstruction, and several measurements, including aortic diameter/volume and sealing lengths. Intraobserver and interobserver agreements were assessed using Bland-Altman analysis and intraclass correlation coefficients (ICCs). Results: We analyzed 133 CTA scans from 31 patients, showing high levels of agreement across measurements, particularly for those repeated by the same observer. Maximum diameter measurements demonstrated excellent consistency, with minimal mean differences for intraobserver and interobserver agreements and excellent correlation (ICC>0.900). Volume measurements were similar consistent, with mean differences of 3.45 (intraobserver) and 2.75 (interobserver) cc. Proximal and distal seal measurements showed good agreement, although interobserver correlation was slightly less consistent. Length of coverage by the endograft exhibited strong consistency. Conclusion: Our standardized measurement protocol for descending TAA offers a consistent approach for preoperative planning, imaging surveillance, and research applications, with high agreement in most measurements. This consistency could reduce variability, enhance imaging surveillance. Future research should focus on external validation, integrating AI to further improve measurement consistency, and simplify TEVAR surveillance. Clinical Impact: This retrospective study of 133 CTA scans from 31 thoracic endovascular aortic repair (TEVAR) for TAA patients demonstrated excellent measurements consistency, including maximum diameter showing strong agreement and minimal differences in volume measurements. In the absence of an existing measurements protocol, our proposed standardized protocol supports improved preoperative planning, imaging surveillance to further enhance TEVAR surveillance.